Phase Ii study with a new alkylating agent (PTT-119) in lymphoid malignancies
Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P.L.; Poletti, G.; Visani, G.; Lemoli, R.M.; Bandini, G.; Cavo, M.; Galieni, P.
Haematologica 73(6): 503-508
1988
ISSN/ISBN: 0390-6078 PMID: 3148513 Document Number: 325242
Document emailed within 1 workday
Related Documents
Sampi, K.; Honda, T.; Hayashi, Y.; Hattori, M. 1983: Phase Ii study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(6): 1538-1539Wang, L.Q.; Zhang, M.G.; Zhu, P. 1993: A study on cellular differentiation and antigen receptor gene rearrangement in lymphoid malignancies Zhonghua Nei Ke Za Zhi 32(10): 673-675
Ueoka, H.; Ueno, K.; Yamane, T.; Toyoda, K.; Endo, H.; Nishihara, R.; Takahashi, I.; Ohnoshi, T.; Kitajima, K.; Kimura, I. 1983: Phase Ii study of mitoxantrone for hematologic malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 10(11): 2399-2402
Yoshida, T.; Nakanishi, J.; Ito, K.; Kobayashi, S.; Ohtake, S.; Nakamura, S.; Hattori, K. 1984: Phase Ii study of etoposide (NK 171) in advanced hematological malignancies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(8): 1579-1584
Murren, J.R.; DiStasio, S.A.; Lorico, A.; McKeon, A.; Zuhowski, E.G.; Egorin, M.J.; Sartorelli, A.C.; Rappa, G. 2000: Phase I and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies Cancer Journal 6(4): 256-265
Miller, J.L.; Hulbert, P.B. 1976: Hycanthone: an alkylating agent [proceeding Journal of Pharmacy and Pharmacology 28 Suppl: 18p
Rosenwald, A. 2003: DNA microarrays in lymphoid malignancies Oncology 17(12): 1743-1748; Discussion 1750 1755 1758-1759 Passim
Iamshchikov, N.V. 1981: Ultrastructural analysis of reactive changes in the myocardium upon embryo exposure to an alkylating agent Arkhiv Anatomii Gistologii i Embriologii 80(3): 64-68
Kotova, D.G.; Zel'dovich, D.R.; Maliugina, L.L. 1975: Use of an alkylating agent from the symm. triazine group on malignant tumors of the ovaries Voprosy Onkologii 21(3): 100-101
Wampler, G.L.; Kuperminc, M.; Regelson, W. 1973: Phase i study of tilorone, a non-marrow depressing antitumor agent Cancer ChemoTherapy Reports 57(2): 209-217
Nomdedéu, J.; Lasa, A.; Seminago, R.; Mateu, R.; Rubiol, E.; Baiget, M.; Soler, J. 1996: Mutational analysis of RAG-1 in lymphoid malignancies Leukemia 10(11): 1715-1718
Russo, J.E.; Hilton, J.; Colvin, O.M. 1989: The role of aldehyde dehydrogenase isozymes in cellular resistance to the alkylating agent cyclophosphamide Progress in Clinical and Biological Research 290: 65-79
Ecknauer, R. 1976: Morphology and enzyme aktivity in rat small intestinal epithelium 6 and 12 hrs. after an alkylating agent (cyclophosphamide) Acta Hepato-Gastroenterologica 23(5): 365-371
Gardella, S.; Cervantes, F.; Bladé, J.; Brugués, R.; Rozman, C. 1982: Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma Medicina Clinica 79(4): 185-188
Shirakawa, S. 1987: Molecular genetical analysis of lymphoid malignancies Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 50(8): 1475-1490
Petersen, F.B.; Buckner, C.D.; Appelbaum, F.R.; Sanders, J.E.; Bensinger, W.I.; Storb, R.; Deeg, H.J.; Witherspoon, R.P.; Sullivan, K.M.; Clift, R.A. 1992: Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study Bone Marrow Transplantation 10(1): 83-88
Dearden, C.E.; Matutes, E.; Catovsky, D. 2000: Clinical overview of pentostatin (Nipent) use in lymphoid malignancies Seminars in Oncology 27(2 Suppl 5: 22-26
Lemoli, R.M.; Visani, G.; Tosi, P.; Mazza, P.; Motta, M.R.; Rizzi, S.; Zinzani, P.L.; Poluzzi, C.; Gherlinzoni, F.; Tura, S. 1988: Effects of a new bifunctional alkylating agent (PTT-119) on in vitro growth of human cell lines and normal myeloid progenitors (CFU-GM) Haematologica 73(3): 195-200
Tobey, R.A.; Tesmer, J.G. 1985: Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan Cancer Research 45(6): 2567-2571
De Rosa, L.; Montuoro, A.; Pandolfi, A.; Lanti, T.; Pescador, L.; Morara, R.; De Laurenzi, A. 1991: Immunomagnetic purging procedure for autologous bone marrow transplantation in lymphoid malignancies Haematologica 76(Suppl 1): 37-40